| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $773.7M | — | +43.2% |
| Cost of Revenue | $433.5M | — | +42.3% |
| R&D Expense | $11.2M | — | +98.3% |
| SG&A Expense | $145.7M | — | +45.6% |
| Operating Income | $39.6M | — | +34.6% |
| Income Tax | $12.3M | — | +54.9% |
| Net Income | $29.2M | — | +28.1% |
| EPS (Basic) | $0.17 | — | +0.0% |
| EPS (Diluted) | $0.16 | — | -5.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $344.2M | +19.1% | — |
| Accounts Receivable | $141.3M | -20.3% | — |
| Inventory | $299.8M | +1.7% | — |
| Current Assets | $807.5M | +1.9% | — |
| Total Assets | $967.2M | +2.1% | — |
| Current Liabilities | $329.5M | -2.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $72.6M | — | +50.0% |
| Capital Expenditures | $9.3M | — | +77.2% |
| Investing Cash Flow | -$9.3M | — | -77.2% |
| Financing Cash Flow | -$8.3M | — | — |
| Free Cash Flow | $63.3M | — | +46.7% |
| Total Liabilities | $357.5M | -2.5% | — |
| Stockholders' Equity | $609.7M | +4.9% | +363.6% |